에 대한 최신 뉴스 Nexa Res (NYSE:NEXA) 주식

Nexa Res

Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.

Commodities

AAUKF

GLCNF

GORO

NEXA

1. 앵글로 아메리칸(OTC:AAUKF)이 BHP 그룹(NYSE:BHP)의 390억 달러의 인수 제의를 거절했다. 이로 인해 글렌코어(OTC:GLCNF)와의 잠재적인 입찰 전쟁이 일어나게 된다. 글렌코어의 관심은 남아프리카 자산 매각에 대한 BHP의 수정된 접근 방식 속에서 발생한다.

금요일 주요 광업 뉴스: 앵글로 아메리칸, 골드 리소스, 트레데거, 넥사 리소스

Equities

Markets

ABAT

RDUS

VALE

2024년 4월 4일 주요 소식:




Radius Recycling (NASDAQ:RDUS)는 제 2분기 재정으로 3,400만 달러(주당 1.19달러의 순손실), 조정된 EBITDA로 300만 달러, 주당 1.04달러의 순손실을 지속 운영사업으로부터 보고했다. 




이번 분기 회사는 리사이클된 금속 공급물의 부족, 불리한 날씨, 미국의 제조 활동이 둔화되는 것과 같은 도전에

목요일 최신 광업 뉴스: 래디우스, 아메리칸 배터리, 넥사 리소스, 뉴몬트, 발리

Nexa Resources SA

Nexalin Technology Inc

Nexans

NEXANS PARIS ACT (FRANCE) by Nexans Paris ACT

Wolfe Research analyst Alexandria Hammond initiates coverage on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Peer Perform rating.

News

Initiation

Analyst Ratings

Wolfe Research Initiates Coverage On Bristol-Myers Squibb with Peer Perform Rating

Wolfe Research analyst Tim Anderson initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Peer Perform rating.

AMGN

Wolfe Research Initiates Coverage On Amgen with Peer Perform Rating

Wolfe Research analyst Akash Tewari initiates coverage on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform rating and announces Price Target of $95.

Price Target

BMRN

Wolfe Research Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating, Announces Price Target of $95

Wolfe Research analyst Alexandria Hammond initiates coverage on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Peer Perform rating.

BIIB

Wolfe Research Initiates Coverage On Biogen with Peer Perform Rating

Wolfe Research analyst Alexandria Hammond initiates coverage on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform rating and announces Price Target of $205.

ABBV

Wolfe Research Initiates Coverage On AbbVie with Outperform Rating, Announces Price Target of $205

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

Reiteration

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $23 price target.

CELC

Needham Reiterates Buy on Celcuity, Maintains $23 Price Target

Needham analyst Ryan Koontz reiterates Gilat Satellite Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) with a Buy and maintains $8.5 price target.

GILT

Needham Reiterates Buy on Gilat Satellite Networks, Maintains $8.5 Price Target

<ul>
<li>Aegon today announces a planned new EUR 150 million share buyback program, consistent with its policy to return excess Cash Capital at Holding to shareholders in the absence of value-creating opportunities. Barring unforeseen circumstances, the share buyback program will start at the beginning of January 2025 and is expected to be completed on or before June 30, 2025. The start of this share buyback program will be announced separately in due course.&nbsp;</li>
<li>The new planned EUR 150 million share buyback program will include an amount of about EUR 40 million to meet Aegon's obligations resulting from the share-based compensation plans for senior management. The repurchased shares resulting from these compensation plans will be held as treasury shares until they are allocated to the plan participants. Aegon intends to cancel the remainder of the repurchased shares resulting from the new planned share buyback program, subject to any relevant approval.</li>
</ul>

Aegon Announces €150M Share Buyback Starting January 2025, With €40M For Compensation And The Rest For Cancellation, Pending Approval

Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has filed a lawsuit against the Health Resources and Services Administration (HRSA). The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount offerings to hospitals.
What Happened: As per Eli Lilly&#8217;s official statement on Thursday, the conflict centers on the federal 340B program, which requires drug manufacturers to offer discounts to healthcare providers serving low-income communities. Participation in this program is crucial for drug companies to secure funding from government health insurance programs like Medicare and Medicaid.
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. However, HRSA, a division of the U.S. Health and Human Services Department, rejected this approach, stating it was inconsistent with the 340B law.
&#8220;HRSA does not have the authority to arbitrarily reject this model, which serves the original goals of the 340B program and improves transparency, efficiency, and program integrity,&#8221; the statement read.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Why It Matters: The lawsuit comes amid ongoing scrutiny of drug pricing practices. Recently, <a href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price">Doctors Without Borders</a> criticized Eli Lilly and other insulin manufacturers for maintaining high prices, urging them to provide affordable insulin to low- and middle-income countries.
This legal action also <a href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs">follows a similar lawsuit</a> by Johnson &amp; Johnson, which alleged the Health and Human Services Department of blocking its drug rebate plans. The 340B program has been subject to extensive legal challenges, with a U.S. appeals court previously allowing drugmakers to limit the use of outside pharmacies for dispensing under the program.
Meanwhile, Eli Lilly has been in the spotlight for its <a href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years">Phase 3 trial data</a> of tirzepatide, marketed as Mounjaro and Zepbound. The study showed promising results in reducing the risk of type 2 diabetes in patients with pre-diabetes and obesity, highlighting the company&#8217;s focus on innovative treatments.
Price Action: Eli Lilly was down by 0.28% during pre-market hours on Friday at the time of writing, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41921267/new-jersey-is-making-history-by-offering-medical-cannabis-as-employee-benefit?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">New Jersey Is Making History By Offering Medical Cannabis</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Biotech

Government

Health Care

General

Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program

Needham analyst James Ricchiuti reiterates 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) with a Hold.

Needham Reiterates Hold on 3D Sys

Aegon trading update for third quarter 2024&nbsp;
• EUR 336 million operating capital generation, before holding funding and operating expenses. Full-year 2024 guidance raised to around EUR 1.2 billion, from around EUR 1.1 billion previously&nbsp;
• Capital ratios of the main units remain above their respective operating levels&nbsp;
• Planned new EUR 150 million share buyback program announced; completion expected in the first half of 2025. The program includes neutralization of shares issued for share-based compensation plans&nbsp;
• Cash Capital at Holding of EUR 1.5 billion as of September 30, 2024. Expect to reach mid-point of the target range (EUR 1.0 billion) by the end of 2026&nbsp;
• Completed program to purchase institutionally owned universal life policies. Terminated policies negatively impacted US RBC ratio by 16%-points. Expect 8%-points benefit in 4Q 2024 after equity funding repayment. Operating capital generation benefits from the program, as previously guided&nbsp;
• Strong commercial momentum in Asset Management and UK Workplace platform. US Strategic Assets experience c

Aegon Q3 Business Update: Operating Capital Generation €336M Before Holding Expenses; Raised FY24 Operating Capital Target To ~€1.2B, Up From The Previous Estimate Of €1.1B

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

GOVX

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Buy and maintains $9 price target.

INKT

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) with a Neutral.

STTK

HC Wainwright & Co. Reiterates Neutral on Shattuck Labs

Macro Economic Events

Econ #s

Economics

U.K. Labour Productivity For Q2 0.2% Vs. 0.1% Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $14 price target.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $14 Price Target

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-cola Europacific Partners Says The Financial Conduct Authority Approved Its Transfer Of Listing Category From Equity Shares Category To Equity Shares (Commercial Companies) Category Of Official List

Michael Burry, the hedge fund manager renowned for predicting the 2008 financial crisis, has significantly increased his exposure to Chinese technology companies while simultaneously implementing protective measures against potential downside risks, <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">according to regulatory filings</a>.
What Happened: Burry&#8217;s Scion Asset Management made several notable adjustments to its portfolio during the third quarter, with Chinese companies now representing its largest positions. The firm increased its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 29%, making it the fund&#8217;s largest holding valued at over $21 million as of September&#8217;s end.
In a similar move, Scion doubled its position in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), elevating it to the fund&#8217;s second-largest holding at approximately $20 million. The firm also expanded its stake in Chinese search giant Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) by 67%, bringing the position to $13.2 million.
However, in what appears to be a cautionary strategy, Burry has simultaneously established put options against these same holdings. Put options typically increase in value when the underlying securities decline, suggesting a hedging strategy designed to protect against potential market volatility.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41999238/ross-gerber-blasts-teslas-support-for-ending-ev-tax-credit-as-insanity-amid-reported-policy-shift-under-trump-administration">Long-Time Tesla Bull Rages As Elon Musk Reportedly Backs Trump&#8217;s Plan To Ax $7.5K EV Credit: &#8216;Insanity&#8217;</a>
The timing of these moves coincides with Beijing&#8217;s recent economic stimulus announcements aimed at reinvigorating growth in the world&#8217;s second-largest economy. While Chinese equities initially rallied in September following these signals, gains have moderated as investors await more concrete fiscal measures.
Beyond his Chinese technology focus, Burry has also increased positions in several U.S. companies, including Shift4 Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), American Coastal Insurance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>), and Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
Why It Matters: Burry&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">top three Chinese holdings</a> have posted average gains of nearly 60% over a two-month period, according to market data.
Burry&#8217;s moves are being closely watched by market participants, particularly given his track record. He gained widespread recognition for his prescient bet against mortgage-backed securities before the 2008 global financial crisis, a story later chronicled in Michael Lewis&#8216;s bestseller &#8220;The Big Short&#8221; and its subsequent Oscar-winning film adaptation.
It&#8217;s worth noting that these positions reflect holdings as of Sep. 30, as required by SEC regulations for funds managing over $100 million in assets. Given the 45-day reporting delay and Burry&#8217;s active trading style, current positions may have already changed.
The development comes as other <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">prominent investors adjust their Chinese holdings</a>. Billionaire investor David Tepper&#8217;s Appaloosa Management recently reduced its Alibaba stake by 5%, though the position remains the fund&#8217;s largest holding at 15.75% of its $6.7 billion portfolio.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">Jim Cramer Says These 10 &#8216;Frothy&#8217; Stocks Are Up Over 200% YTD, Including Rocket Lab, Palantir, And Carvana</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Global

ACIC

BABA

BIDU

FOUR

'Big Short' Investor Michael Burry Doubles Down On Chinese Tech Stocks While Adding Protective Hedges

NATL

NCR Atleos Inks Five-year Agreement To Provide Atleos' Cashzone Network ATMs In The John Lewis Partnership's Waitrose Supermarkets Across The UK

Nexa Resources SA (NEXA) has released an update. Nexa Resources SA has reaffirmed its total mining production guidance for zinc and lead in 2024, w...

Nexa Resources Updates Production and Cost Forecasts for 2024

Nexa Resources lowers capex guidance

Nexa Resources SA (NEXA) has released an update. Nexa Resources S.A. reported a significant improvement in its financial performance for the third ...

Nexa Resources Sees Revenue Growth Amid Net Loss

Nexa Resources Non-GAAP EPS of $0.02 misses by $0.16

Nexa Resources SA (NEXA) has released an update. Nexa Resources SA reported a net income of $6 million and an adjusted EBITDA of $183 million for t...

Nexa Resources SA Achieves Strong Q3 2024 Results

Nexa Resources reports Q3 results

Bank of America Securities analyst Lawson Winder maintained a Sell rating on Nexa Resources SA (NEXA – Research Report) yesterday and set a price t...

Cautious Outlook on Nexa Resources SA Amid Operational Challenges and Financial Constraints

Nexa Resources ( ($NEXA) ) has released its Q3 earnings. Here is a breakdown of the information Nexa Resources presented to its investors. Nexa Res...

Nexa Resources Reports Solid Q3 2024 Earnings

In a report released today, Orest Wowkodaw from Scotiabank maintained a Sell rating on Nexa Resources SA (NEXA – Research Report), with a price tar...

Scotiabank Sticks to Their Sell Rating for Nexa Resources SA (NEXA)

Scotiabank analyst Orest Wowkodaw lowered the firm's price target on Nexa Resources (NEXA) to $5.75 from $6 and keeps an Underperform rating on the...

Nexa Resources price target lowered to $5.75 from $6 at Scotiabank

Press Releases

Nexa Resources Publishes Its 2023 Sustainability Report

Earnings

Nexa Reports First Quarter 2024 Results Including Net Loss of US$11 Million and Adjusted EBITDA of US$123 Million

Nexa Resources S.A. Reports Voting Results From Annual General Meeting

Nexa Resources Announces Closing Transaction of Morro Agudo Complex Sale to Casa Verde

Nexa Reports Second Quarter 2024 Exploration Results

Nexa Resources Reports Solid Operational Performance and Financial Results in 2Q24

Nexa Resources Announces Board and Management Changes

Nexa Reports Third Quarter 2024 Exploration Results

Nexa Provides 2024 Guidance Update

Nexa Resources Announces Solid 3Q24 Results with Net Income of US$6 Million and Adjusted EBITDA of US$183 million

LOMA

American Battery Technology Company - Common Stock

American Battery Tech

BHP Group Limited American Depositary Shares (Each representing two Ordinary Shares)

BHP Group

Compass Minerals Intl

Critical Metals

Contango Ore

5E Advanced Materials, Inc. - Common Stock

5E Advanced Materials

Ferroglobe

Idaho Strategic Resources, Inc. Common Stock

Idaho Strategic Resources

Ivanhoe Electric

Ioneer

Snow Lake Resources

Lifezone Metals

MP Materials

Materion

Nova Minerals Limited - American Depositary Shares

Nova Minerals

Piedmont Lithium

TMC the metals company Inc. - Common Stock

TMC Metals

United States Antimony Corporation Common Stock

United States Antimony

U.S. Gold

US Goldmining

Solitario Resources

Scotiabank

B of A Securities

Morgan Stanley

BMO Capital

JP Morgan

1. 앵글로 아메리칸(OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTC">AAUKF</a>)이 BHP 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>)의 390억 달러의 인수 제의를 거절했다. 이로 인해 글렌코어(OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLCNF#OTC">GLCNF</a>)와의 잠재적인 <a href="https://www.benzinga.com/m-a/24/05/38612588/potential-bidding-war-emerges-for-anglo-american-as-glencore-considers-offer">입찰 전쟁</a>이 일어나게 된다.
글렌코어의 관심은 남아프리카 자산 매각에 대한 BHP의 수정된 접근 방식 속에서 발생한다.
앵글로는 칠레와 페루에서 중요한 구리 매장량을 보유하고 있으며 콜라후아시(Collahuasi)에 대한 글렌코어의 지분이 흥미를 더하고 있다.
그러나 글렌코어의 69억 달러 규모의 테크 리소스(Teck Reseources) 석탄 인수와 다가오는 총선을 포함해 남아프리카공화국의 정치적 및 규제적 복잡성은 이 상황을 더 악화시킨다.
BHP는 새로운 입찰 마감일인 5월 22일을 앞두고 있다.
2. 골드 리소스(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GORO#AMEX">GORO</a>)는 멕시코 오악사카의 돈 다비드(Don David) 금광에서의 제 1분기 결산 결과와 기업 업데이트를 공표했다.
주요 성과에는 금 3,557온스, 은 216,535온스, 상당한 양의 아연, 구리 및 납의 생산 및 판매가 포함되었다.
2024년 3월 31일 기준 이 회사는 부채 없이 현금 570만 달러, 운전 자본 1,360만 달러를 보유하고 있다.
공장 생산량 감소, 회수율 감소 등의 문제는 잘 해결되었으며, 비철금속 가격은 예상보다 낮았다.
이번 분기에는 탐사 및 시추 관련 비용을 제외하고 400만 달러 또는 주당 5센트의 순손실이 기록되었다.
골드 등가 온스당 총 현금 비용은 1,667달러이며, 올인 지속 비용은 2,295달러였다.
3. 미국 상무부는 중국, 인도, 이탈리아 등 14개국 알루미늄 압출 생산업체가 미국에서 제품을 공정한 가격보다 낮은 가격에 판매했다는 예비 조사 결과를 발표했다.
미국 알루미늄 압출 생산자 연합과 다양한 노동 조합은 미국 생산자와 근로자를 보호하기 위한 이러한 조세의 부과를 지지한다.
이러한 조치는 덤핑 마진의 정확한 최종 결정을 보장하기 위한 지속적인 노력과 함께 미국 산업에 해를 끼치는 광범위한 덤핑 관행에 대응하는 데 중요하다.
트레데거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TG#NYSE">TG</a>)의 계열사인 본넬 알루미늄(Bonnell Aluminum)은 알루미늄 압출물의 불공정한 무역 수입품에 대한 예비 덤프팅 조세 부과 판결에 만족했다.
4. 넥사 리소스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>)는 분기별 주당 15센트의 손실을 보고했는데, 이는 전년 대비 손실이 1400% 증가했다.
그럼에도 불구하고 분기 매출 5억 8천만 달러는 예상치를 1.76% 초과했지만, 전년 대비 13.08% 감소했다.
또한 이 회사는 엘뽀르베니르(El Porvenir) 광산과 바잔테(Vazante) 광산에서 두 건의 사망 사고에 직면했다.
약한 시장 여건과 원자재 가격 변동 등의 어려움 속에서도 넥사는 우리푸낭(Aripuanã) 증설 및 세로 파스코(Cerro Pasco) 통합 프로젝트와 같은 주요 프로젝트를 계속해서 추진했다. 이로 인해 단지의 광물 매장량은 59% 증가하고 전체 광물 매장량은 전년 대비 10% 증가하여 총 1억 1천만 톤에 달한다.
벤징가 마이닝은 채굴 기업과 소매 투자자 사이의 연결고리입니다. <a href="https://www.benzinga.com/">licensing@benzinga.com</a> 으로 연락하여 벤징가 커뮤니티와 관계를 맺어 보십시오. 
사진: 셔터스톡

2024년 4월 4일 주요 소식:
1. 래디우스 리사이클링(Radius Recycling) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDUS#NASDAQ">RDUS</a>)는 회계연도 2분기 재정으로 3,400만 달러 손실(주당 1.19달러의 손실), 조정된 EBITDA로 300만 달러, 주당 1.04달러의 손실을 <a href="https://www.benzinga.com/news/earnings/24/04/38088715/schnitzer-steel-q2-adj-1-04-beats-1-09-estimate-sales-621-06m-miss-626-15m-estimate">지속 운영사업으로부터</a> 보고했다.
이번 분기 회사는 리사이클된 금속의 공 부족, 불리한 날씨, 미국의 제조 활동이 둔화되는 것과 같은 도전에 직면했다.
철 매출은 전분기 대비 15% 감소했고, 비철 매출은 전년 동기 대비 3% 감소했지만 7% 성장했으며, 완제품 매출은 전년 동기 대비 5% 증가했지만 전분기 대비 11% 감소했다.
회사는 판매관리비(SG&amp;A)를 10% 삭감하고 생산 효율성을 향상시키는 계획을 시작했다. 연간 이익 4천만 달러를 목표로 하고 이전 혜택 계획 3천만 달러에 추가했다.
2. 아메리칸 배터리 테크놀러지(American Battery Technology) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>)는 미국 내 새로운 배터리 재활용 시설에 대한 48C 프로그램을 통한 4,050만 달러의 추가 지원을 받았다. 이는 네바다 프로젝트를 위한 초기 2,000만 달러의 세액이행을 더하는 것이다.
이번 수상은 미국 에너지부가 기업의 저비용, 환경 친화적인 리튬이온 배터리 재활용 및 재생 배터리 재료 제조 노력을 지원하는 과정에서 이루어졌다.
최고경영자(CEO) 라이언 멜서트(Ryan Melsert)는 주요 자동차 및 배터리 제조업체와의 방대한 협력을 언급하였으며, 이 새로운 시설이 미국의 중요한 배터리 광물 생산을 촉진하는 것을 계획하고, 이를 위해 이번 정부 지원 투자를 활용할 것이라고 밝혔다.
기사 더 읽기:Gold Fields, 중국 장관 생산 전망 부상
3. 넥사 리소스(Nexa Resources) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>)는 2034년 만기의 두 자회사 보증으로 6.75%의 선순위 무담보 채권 6억 달러의 공모를 가격을 책정하였으며, 이번 공모는 2024년 4월 9일마감을 목표로 한다.
이번 매각 수익금은 2027년과 2028년 만기 기존의 채권에 대한 현금 양도요청을 통한 자금 준비를 위주로 하고 있으며, 그 외에는 일반 기업 목적을 위해 사용될 것이다.
이번 판매는 자격을 갖춘 기관 구매자와 미국인이 아닌 사람을 대상으로 한다.
4. Benzinga가 공공 옵션 활동을 추적한 결과 9건의 주목할만한 거래에서 비정상적인 활동이 감지된 것처럼 대규모 투자자들은 뉴몬트(Newmont) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)에 대해 주로 약세 입장을 보이고 있다.
이러한 투자자들 간의 심리는 44%의 상승세와 55%의 하락세를 보이고 있다. 이번 거래에는 250,920달러 상당의 풋옵션 2개와 805,535달러 상당의 콜옵션 7개가 포함되었으며, 이는 향후 3개월 동안 뉴몬트의 예상 가격 범위가 30~42.50달러임을 시사한다.
5. 도이체 방크의 애널리스트인 리암 피츠패트릭(Liam Fitzpatrick)은 발리(Vale S.A.) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>)에 대한 평가를 중립(Hold)으로 유지하였으며, 이에 따라 <a href="https://www.benzinga.com/quote/VALE/analyst-ratings">18달러에서 16달러로</a> <a href="https://www.benzinga.com/quote/VALE/analyst-ratings">목표주가</a>를 낮췄다.
기사 더 읽기: <a href="https://www.benzinga.com/">Will Copper Reach $10,000? &#8216;An Essential Metal That Faces An Uncertain Future&#8217;</a>
Benzinga Mining은 채굴 기업과 개인 투자자 사이의 다리 역할을 합니다. Benzinga 커뮤니티와 연결하려면 <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a> 으로 연락하십시오! 
MidJourney를 통해 인공 지능을 활용하여 작성된 일러스트

Comments

Nexa Res

뉴스

에 대한 최신 뉴스 Nexa Res (NYSE:NEXA) 주식

금요일, 5월 03, 2024

목요일, 4월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌